2011年

The ESCRT system is required for hepatitis C virus production.
Ariumi Y, Kuroki M, Maki M, Ikeda M, Dansako H, Wakita T, Kato N.
PLoS One, 6:e14517 (2011)

Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system.
Mori K, Ikeda M, Ariumi Y, Dansako H, Wakita T, Kato N.
Virus Res., 151(1):61-70 (2011)

Anti-ulcer agent teprenone inhibits hepatitis C virus replication: Potential treatment for hepatitis C.
Ikeda M, Kawai Y, Mori K, Yano M, Abe K, Nishimura G, Dansako H, Ariumi Y, Wakita T, Yamamoto K, Kato N.
Liver Int., 31(6):871-80 (2011)

Hepatitis C virus hijacks P-body and stress granule components around lipid droplets.
Ariumi Y, Kuroki M, Kushima Y, Osugi K, Hijikata M, Maki M, Ikeda M, Kato N.
J. Virol., 85(14):6882-92 (2011)

Plural assay systems derived from different cell lines and hepatitis C virus strains are required for the objective evaluation of anti-hepatitis C virus reagents.
Ueda Y, Mori K, Ariumi Y, Ikeda M, Kato N.
Biochem. Biophys. Res. Commun., 409(4):663-8 (2011)

I-mfa domain proteins specifically interact with SERTA domain proteins and repress their transactivating functions.
Kusano S, Shiimura Y, Eizuru Y.
Biochimie, 93(9):1555-64 (2011)